Gonçalves Gabriele Teixeira, Santos Luciana Martins de Mello, Figueiredo Pedro Henrique Scheidt, Freitas Jaqueline de Paula Chaves, Santos Jousielle Márcia, Santos Joyce Noelly Vitor, Junior Fidelis Antônio da Silva, Alves Frederico Lopes, Brandão Vanessa Gomes, Maciel Emílio Henrique Barroso, Prates Maria Cecília S M, Sañudo Borja, Taiar Redha, Bernardo-Filho Mario, Sá-Caputo Danúbia da Cunha de, Lima Vanessa Pereira, Silveira Henrique, Gripp Victor Lacerda, Mendonça Vanessa Amaral, Lacerda Ana Cristina Rodrigues
Centro Integrado de Pós-Graduação e Pesquisa em Saúde (CIPq-Saúde), Universidade Federal dos Vales do Jequitinhonha e Mucuri, Diamantina, Brazil.
Laboratório de Fisiologia do Exercício - LAFIEX - CIPq/Saúde, Universidade Federal dos Vales do Jequitinhonha e Mucuri, Diamantina, Brazil.
PLoS One. 2025 Apr 29;20(4):e0320019. doi: 10.1371/journal.pone.0320019. eCollection 2025.
Patients on hemodialysis commonly present with elevated inflammatory markers. It is noteworthy, however, that higher levels of these markers may deteriorate residual renal function in in these individuals. Further investigation is essential to clarify the potential link between systemic chronic inflammatory parameters and residual diuresis volume in this population, particularly when accounting for confounding variables such as body composition. This study aimed to explore the possible relationship between inflammatory parameters and residual diuresis volume in patients on hemodialysis.
Blood samples were collected from patients on hemodialysis for the analysis of soluble receptors: 1) tumor necrosis factor receptor 1 (sTNFR1), 2) tumor necrosis factor receptor 2 (sTNFR2), and 3) leptin. Confounding variables, such as gender, age, duration of hemodialysis, Kt/V (a measure of dialysis adequacy), and body composition assessed using the dual-energy X-ray absorptiometry (DXA), were also evaluated. Data analyses were conducted using both single and multiple regression models, adjusted for the confounding parameters.
Of the total sixty participants, 27 (45%) were classified as anuric, and 33 (55%) as non-anuric. High sTNFR1 plasma levels were associated with a lower residual diuresis volume, irrespective of adjustments for confounding parameters (R² = 25.4%; β = 0.504; p < 0.001).
This study supports the hypothesis that higher systemic levels of sTNFR1 may deteriorate residual renal function, as evidenced by the lower residual diuresis volume observed in patients on hemodialysis. These findings suggest that interventions aimed at reducing systemic inflammation may be beneficial in preserving residual renal function and improving clinical outcomes in these patients. Chronic Kidney Disease (CKD) is characterized by any persistent alteration or abnormality in kidney structure or function lasting over ninety days [1]. CKD's subtle onset complicates diagnosis, and once established, it often progresses irreversibly [2]. Recognized globally as a major public health issue [3], CKD affects 10-13% of adults in economically advanced countries [1]. In Brazil, CKD poses significant healthcare challenges, causing over 35,000 deaths annually and incurring substantial treatment costs [4]. Projections indicate around 10 million CKD cases in Brazil, with about 90,000 individuals requiring dialysis [5,6]. This data underscores the urgent need to address CKD as a critical health challenge and develop comprehensive strategies to mitigate its impact on public health and healthcare costs.
接受血液透析的患者通常存在炎症标志物升高的情况。然而,值得注意的是,这些标志物水平升高可能会使这些个体的残余肾功能恶化。进一步的研究对于阐明该人群全身慢性炎症参数与残余尿量之间的潜在联系至关重要,尤其是在考虑诸如身体成分等混杂变量时。本研究旨在探讨血液透析患者炎症参数与残余尿量之间的可能关系。
采集接受血液透析患者的血样,用于分析可溶性受体:1)肿瘤坏死因子受体1(sTNFR1)、2)肿瘤坏死因子受体2(sTNFR2)和3)瘦素。还评估了混杂变量,如性别、年龄、血液透析持续时间、Kt/V(透析充分性的一种衡量指标)以及使用双能X线吸收法(DXA)评估的身体成分。使用单因素和多因素回归模型进行数据分析,并对混杂参数进行了调整。
在总共60名参与者中,27名(45%)被归类为无尿,33名(55%)为非无尿。无论对混杂参数如何调整,sTNFR1血浆水平升高均与较低的残余尿量相关(R² = 25.4%;β = 0.504;p < 0.001)。
本研究支持以下假设,即sTNFR1全身水平升高可能会使残余肾功能恶化,血液透析患者中观察到的较低残余尿量证明了这一点。这些发现表明,旨在减轻全身炎症的干预措施可能有助于保护残余肾功能并改善这些患者的临床结局。慢性肾脏病(CKD)的特征是肾脏结构或功能持续90天以上出现任何持续性改变或异常[1]。CKD起病隐匿,诊断困难,一旦确诊,往往会不可逆转地进展[2]。CKD在全球被公认为一个主要的公共卫生问题[3],在经济发达国家,10 - 13%的成年人受其影响[1]。在巴西,CKD带来了重大的医疗挑战,每年导致超过35000人死亡,并产生巨额治疗费用[4]。据预测,巴西约有1000万例CKD病例,约90000人需要透析[5,6]。这些数据凸显了迫切需要将CKD作为一项关键的健康挑战加以应对,并制定全面战略以减轻其对公共卫生和医疗费用的影响。